Alimta

... ots.at: Lilly Launches Phase III Trial of Targeted Cancer Agent text.ots.atmobile.ots.at presseportal.at tourismuspresse.at euroadhoc.com politikportal.at ---- presseportal.de presseportal.ch Home < Wirtschaft < Volltext Kontakt Impressum Profisuche Hilfe E-Mail Passwort Login Erstanmeldung Hilfe Für AOM-User Ohne AOM-Account Hilfe Produkte & Preise Eli Lilly and Company / 09.03.2006 / 12:06 / OTE0008 5 WA 0818 PRN0010 Lilly Launches Phase III Trial of Targeted Cancer AgentIndianapolis (ots/PRNewswire) - - Enzastaurin Study Enrolling Patients with Glioblastoma One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

"Glioblastoma is a devastating disease for patients often slowly impacting their cognitive thinking and emotional responses," said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Eli Lilly and Company.

"Through its distinct mechanism of action, preclinical studies suggest that enzastaurin attacks the tumor in multiple ways.

While there have been some recent advances in treating this devastating disease, survival rates are still low.

Enzastaurin is a promising agent, and we look forward ...

Read more...